Cargando…

Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy

BACKGROUND: The kidney is a major target in primary antiphospholipid syndrome. Several types of nephropathy have been reported, the most frequent being acute or chronic specific vascular nephropathies and membranous nephropathy. CASE PRESENTATION: A 59-year-old male presented in our unit with nephro...

Descripción completa

Detalles Bibliográficos
Autores principales: Teisseyre, Maxime, Perrochia, Hélène, Reboul, Pascal, Cariou, Sylvain, Renaud, Sophie, Aglae, Cédric, Moranne, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247250/
https://www.ncbi.nlm.nih.gov/pubmed/32448215
http://dx.doi.org/10.1186/s12882-020-01856-z
_version_ 1783538120841494528
author Teisseyre, Maxime
Perrochia, Hélène
Reboul, Pascal
Cariou, Sylvain
Renaud, Sophie
Aglae, Cédric
Moranne, Olivier
author_facet Teisseyre, Maxime
Perrochia, Hélène
Reboul, Pascal
Cariou, Sylvain
Renaud, Sophie
Aglae, Cédric
Moranne, Olivier
author_sort Teisseyre, Maxime
collection PubMed
description BACKGROUND: The kidney is a major target in primary antiphospholipid syndrome. Several types of nephropathy have been reported, the most frequent being acute or chronic specific vascular nephropathies and membranous nephropathy. CASE PRESENTATION: A 59-year-old male presented in our unit with nephrotic syndrome. He had a history of primary antiphospholipid syndrome with lupus anticoagulant treated with vitamin K antagonist therapy. On admission, antiphospholipid (lupus anticoagulant) and anti-PLA2R antibodies were positive. Screening for secondary etiologies was negative. In the context of primary antiphospholipid syndrome treated with vitamin K antagonist therapy, we did not perform a biopsy and we treated the patient with angiotensin-converting-enzyme inhibitor. No remission was observed at 6 months with persistent anti-PLA2R antibodies while antiphospholipid antibody level became negative. Consequently, kidney biopsy was performed showing both membranous nephropathy with PLA2R in deposits on immunohistochemistry with IgG4 dominance and antiphospholipid syndrome chronic vascular nephropathy. Following that, treatment with rituximab was started with secondarily a decrease in serum PLA2R antibody levels and partial remission. CONCLUSION: We report the first association between primary antiphospholipid syndrome and membranous nephropathy with anti-PLA2R antibodies. Our observations could suggest a causal link between primary antiphospholipid syndrome and PLA2R-related membranous nephropathy. Consequently, it would be interesting to screen for anti-PLA2R antibodies for further cases of nephrotic syndrome in patients with primary antiphospholipid syndrome and to search antiphospholipid antibodies in all membranous nephropathies.
format Online
Article
Text
id pubmed-7247250
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72472502020-06-01 Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy Teisseyre, Maxime Perrochia, Hélène Reboul, Pascal Cariou, Sylvain Renaud, Sophie Aglae, Cédric Moranne, Olivier BMC Nephrol Case Report BACKGROUND: The kidney is a major target in primary antiphospholipid syndrome. Several types of nephropathy have been reported, the most frequent being acute or chronic specific vascular nephropathies and membranous nephropathy. CASE PRESENTATION: A 59-year-old male presented in our unit with nephrotic syndrome. He had a history of primary antiphospholipid syndrome with lupus anticoagulant treated with vitamin K antagonist therapy. On admission, antiphospholipid (lupus anticoagulant) and anti-PLA2R antibodies were positive. Screening for secondary etiologies was negative. In the context of primary antiphospholipid syndrome treated with vitamin K antagonist therapy, we did not perform a biopsy and we treated the patient with angiotensin-converting-enzyme inhibitor. No remission was observed at 6 months with persistent anti-PLA2R antibodies while antiphospholipid antibody level became negative. Consequently, kidney biopsy was performed showing both membranous nephropathy with PLA2R in deposits on immunohistochemistry with IgG4 dominance and antiphospholipid syndrome chronic vascular nephropathy. Following that, treatment with rituximab was started with secondarily a decrease in serum PLA2R antibody levels and partial remission. CONCLUSION: We report the first association between primary antiphospholipid syndrome and membranous nephropathy with anti-PLA2R antibodies. Our observations could suggest a causal link between primary antiphospholipid syndrome and PLA2R-related membranous nephropathy. Consequently, it would be interesting to screen for anti-PLA2R antibodies for further cases of nephrotic syndrome in patients with primary antiphospholipid syndrome and to search antiphospholipid antibodies in all membranous nephropathies. BioMed Central 2020-05-24 /pmc/articles/PMC7247250/ /pubmed/32448215 http://dx.doi.org/10.1186/s12882-020-01856-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Teisseyre, Maxime
Perrochia, Hélène
Reboul, Pascal
Cariou, Sylvain
Renaud, Sophie
Aglae, Cédric
Moranne, Olivier
Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
title Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
title_full Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
title_fullStr Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
title_full_unstemmed Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
title_short Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
title_sort primary antiphospholipid syndrome associated with anti-phospholipase a2 receptor antibody-positive membranous nephropathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247250/
https://www.ncbi.nlm.nih.gov/pubmed/32448215
http://dx.doi.org/10.1186/s12882-020-01856-z
work_keys_str_mv AT teisseyremaxime primaryantiphospholipidsyndromeassociatedwithantiphospholipasea2receptorantibodypositivemembranousnephropathy
AT perrochiahelene primaryantiphospholipidsyndromeassociatedwithantiphospholipasea2receptorantibodypositivemembranousnephropathy
AT reboulpascal primaryantiphospholipidsyndromeassociatedwithantiphospholipasea2receptorantibodypositivemembranousnephropathy
AT cariousylvain primaryantiphospholipidsyndromeassociatedwithantiphospholipasea2receptorantibodypositivemembranousnephropathy
AT renaudsophie primaryantiphospholipidsyndromeassociatedwithantiphospholipasea2receptorantibodypositivemembranousnephropathy
AT aglaecedric primaryantiphospholipidsyndromeassociatedwithantiphospholipasea2receptorantibodypositivemembranousnephropathy
AT moranneolivier primaryantiphospholipidsyndromeassociatedwithantiphospholipasea2receptorantibodypositivemembranousnephropathy